Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-Cola HBC Regulatory News (CCH)

Share Price Information for Coca-Cola HBC (CCH)

Share Price is delayed by 15 minutes
Get Live Data
4,542.00    -44.00 (-0.96%)
Bid:
4,546.00
Ask:
4,550.00
Spread: 4.00 (0.088%)
Market Cap: £16.55b
CCH Live PriceLast checked at - London Stock Exchange

Intraday Coca-Cola HBC Share Chart

Director/PDMR Shareholding

21 Mar 2023 09:48

RNS Number : 7195T
Coca-Cola HBC AG
21 March 2023
Ā 

FOR IMMEDIATE RELEASE

21 March 2023

Ā 

Coca-Cola HBC AG (the "Company")

Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs')

The Company announces that on 17 March 2023, a deferred bonus award was granted to the Chief Executive Officer over shares of CHF 6.70 in the Company relating to a performance related annual bonus for 2022 under the terms of the Company's Management Incentive Plan (the "Deferred Shares"):

Ā PDMR

Position

Number of Deferred Shares granted

ZORAN BOGDANOVIC

CEO

18,941

Ā 

The Notification of Dealing Form can be found below.

1

Ā 

Details of the person discharging managerial responsibilities / person closely associated

a)

Ā 

Name

Ā 

ZORAN BOGDANOVIC

Ā 

2

Ā 

Reason for the notification

a)

Ā 

Position/status

Ā 

CHIEF EXECUTIVE OFFICER

b)

Ā 

Initial notification /Amendment

Ā 

INITIAL NOTIFICATION

3

Ā 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Ā 

Name

Ā 

COCA-COLA HBC AG

b)

Ā 

LEI

Ā 

549300EFP3TNG7JGVE49

4

Ā 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Ā 

Description of the financial instrument, type of instrument

Ā 

Identification code

Ā 

Ā 

SHARES

Ā 

Ā 

CH0198251305

b)

Ā 

Nature of the transaction

Ā 

Ā 

GRANT OF DEFERRED SHARES UNDER THE MANAGEMENT INCENTIVE PLAN. THE NUMBER OF DEFERRED SHARES GRANTED IS EQUIVALENT TO 50 PER CENT OF THE ANNUAL BONUS AWARDED TO THE CHIEF EXECUTIVE OFFICER FOR THE 2022

FINANCIAL YEAR, CALCULATED ON THE BASIS OF THE CLOSING PRICE FOR THE DEFERRED SHARES ON THE DATE OF GRANT. THE DEFERRED SHARES WILL HAVE A VESTING PERIOD OF THREE YEARS FROM 31 DECEMBER 2022.

c)

Ā 

Price(s) and volume(s)

Ā 

Ā 

Ā 

Price(s)

Volume(s)

21.18 GBP

18,941

d)

Ā 

Aggregated information

Ā 

- Aggregated volume

Ā 

- Price

Ā 

Ā 

Price

Volume

Total

21.18 GBP

18,941

401,170.38 GBP

e)

Ā 

Date of the transaction

Ā 

2023-03-17

f)

Ā 

Place of the transaction

Ā 

OUTSIDE A TRADING VENUE

Ā 

This notification is made in accordance with the requirements of the UK Market Abuse Regulation and EU Market Abuse Regulation.

For further information, please contact:

Jan Gustavsson

General Counsel and Company Secretary

+41 (0) 41 726 01 10

Ā 

Ā 

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
DSHNKDBQCBKKFNB
Date   Source Headline
19th May 20229:20 amRNSNotice of AGM
18th May 20223:05 pmRNSDirector/PDMR Shareholding
18th May 202212:24 pmRNSHolding(s) in Company
12th May 20227:00 amRNSStrong performance despite turbulent environment
3rd May 202210:22 amRNSIssue of equity and total voting rights
3rd May 202210:05 amRNSBlock listing Interim Review
29th Apr 20221:46 pmRNSHolding(s) in Company
20th Apr 20223:03 pmRNSDirector/PDMR Shareholding
19th Apr 202210:06 amRNSNotice of Results
12th Apr 20225:38 pmRNSMove to organic reporting
1st Apr 20223:58 pmRNSDirector/PDMR Shareholding
1st Apr 20223:47 pmRNSDirector/PDMR Shareholding
1st Apr 202211:46 amRNSIssue of equity and total voting rights
23rd Mar 202212:23 pmRNSAnnual Financial Report
18th Mar 20222:02 pmRNSDirector/PDMR Shareholding
16th Mar 20223:43 pmRNSDirector/PDMR Shareholding
16th Mar 202212:56 pmRNSDirector/PDMR Shareholding
14th Mar 202210:57 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSUkraine and Russia update
3rd Mar 20224:31 pmRNSDirector/PDMR Shareholding
3rd Mar 20227:00 amRNSUkraine and Russia conflict update
22nd Feb 20227:00 amRNSSTRONG EXECUTION DRIVES GROWTH MOMENTUM
18th Feb 20222:45 pmRNSDirector/PDMR Shareholding
2nd Feb 20229:57 amRNSNotice of Results
1st Feb 20228:20 amRNSIssue of equity and total voting rights
25th Jan 202212:50 pmRNSCompletes acquisition of further stake in CCBCE
18th Jan 20222:20 pmRNSDirector/PDMR Shareholding
13th Jan 20228:53 amRNSCompletes acquisition of a majority stake in CCBCE
7th Jan 20222:14 pmRNSAthens Exchange trading date of ordinary shares
4th Jan 202210:55 amRNSIssue of equity and total voting rights
4th Jan 20229:54 amRNSDirector/PDMR Shareholding
31st Dec 202110:27 amRNSDirector/PDMR Shareholding
31st Dec 202110:19 amRNSDirector/PDMR Shareholding
20th Dec 20213:58 pmRNSDirector/PDMR Shareholding
20th Dec 20213:43 pmRNSDirector/PDMR Shareholding
17th Dec 20213:38 pmRNSPost 2021 AGM Shareholder Engagement
13th Dec 20213:29 pmRNSDirector/PDMR Shareholding
7th Dec 202110:29 amRNSDirector/PDMR Shareholding
1st Dec 20218:34 amRNSIssue of equity and total voting rights
18th Nov 20211:12 pmRNSDirector/PDMR Shareholding
15th Nov 20213:16 pmRNSDirector/PDMR Shareholding
15th Nov 20212:03 pmRNSDirector/PDMR Shareholding
12th Nov 20219:17 amRNSDirector/PDMR Shareholding
12th Nov 20218:45 amRNSDirector/PDMR Shareholding
11th Nov 202111:57 amRNSDirector/PDMR Shareholding
3rd Nov 20217:00 amRNSFocused strategy drives acceleration in growth
1st Nov 20219:18 amRNSBlock listing Interim Review
1st Nov 20218:49 amRNSIssue of equity and total voting rights
19th Oct 202111:58 amRNSDirector/PDMR Shareholding
14th Oct 20219:53 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.